Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS) Clinical Trial

Official title:

Single Arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin Alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02175277
• Other study ID #: 20130113
• Secondary ID: 2013-000727-13
• Status: Completed
• Phase: Phase 3
• Start date: June 12, 2014
• Est. completion date: March 20, 2017

Study information

• Verified date: October 2018
• Source: Amgen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for patients who had continued demonstration of benefit from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient population.

Description:

This is a phase 3b, multi-centre, open-label, single-arm companion study to the MDS 20090160 study (NCT01362140) for the treatment of anaemic patients with MDS. Participants who completed the active-treatment period of the darbepoetin alfa MDS 20090160 study and met the eligibility criteria could be enrolled into this study to continue treatment of darbepoetin alfa for up to 73 weeks or until progression to acute myelogenous leukemia (AML), whichever occurs first.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: March 20, 2017
• Est. primary completion date: March 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/ procedures being initiated;

• Subject must continue long term follow up within parent study (20090160);

• Subject must have an ongoing clinically relevant erythroid response as assessed by the Investigator using current response criteria (ie, International Working Group (IWG) response criteria);

Exclusion Criteria:

• Transfusion dependence defined as receiving a total of = 4 units of red blood cell (RBC) transfusion in the previous 8-week period prior to enrolment;

• Known diagnosis of acute myelogenous leukemia (AML) or marrow collagen fibrosis;

• Known refractory anaemia with excess blast-2 (RAEB-2);

• Known diagnosis of intermediate-2 or high risk MDS per International Prognostic Scoring System (IPSS);

• Subjects received thrombopoiesis-stimulating factors (eg, eltrombopag, romiplostim) in the MDS 20090160 study or planning to receive such agents during the study;

• Other protocol defined inclusion and exclusion criteria may apply.

Related Conditions & MeSH terms

• Myelodysplastic Syndrome (MDS)
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• Darbepoetin Alfa
The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 µg every two weeks (Q2W).

Locations

Country	Name	City	State
Belgium	Research Site	Charleroi
Belgium	Research Site	Leuven
Belgium	Research Site	Liege
Belgium	Research Site	Sint-Niklaas

Sponsors (1)

Lead Sponsor	Collaborator
Amgen

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-emergent Adverse Events	Adverse events (AEs) were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, where Grade 1 indicates a mild AE, Grade 2 indicates a moderate AE, Grade 3 indicates severe or medically significant but not immediately life-threatening and Grade 4 indicates life-threatening consequences; urgent intervention indicated.; A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: fatal; life threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event The investigator assessed whether each adverse events was related to darbepoetin alfa.	From first dose of darbepoetin alfa to 30 days after last dose; the maximum treatment duration was 73 weeks.

External Links

•   AmgenTrials clinical trials website